|
|
The FGF metabolic axis |
Xiaokun Li() |
School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou 325035, China |
|
|
Abstract Members of the fibroblast growth factor (FGF) family play pleiotropic roles in cellular and metabolic homeostasis. During evolution, the ancestor FGF expands into multiple members by acquiring divergent structural elements that enable functional divergence and specification. Heparan sulfate-binding FGFs, which play critical roles in embryonic development and adult tissue remodeling homeostasis, adapt to an autocrine/paracrine mode of action to promote cell proliferation and population growth. By contrast, FGF19, 21, and 23 coevolve through losing binding affinity for extracellular matrix heparan sulfate while acquiring affinity for transmembrane α-Klotho (KL) or β-KL as a coreceptor, thereby adapting to an endocrine mode of action to drive interorgan crosstalk that regulates a broad spectrum of metabolic homeostasis. FGF19 metabolic axis from the ileum to liver negatively controls diurnal bile acid biosynthesis. FGF21 metabolic axes play multifaceted roles in controlling the homeostasis of lipid, glucose, and energy metabolism. FGF23 axes from the bone to kidney and parathyroid regulate metabolic homeostasis of phosphate, calcium, vitamin D, and parathyroid hormone that are important for bone health and systemic mineral balance. The significant divergence in structural elements and multiple functional specifications of FGF19, 21, and 23 in cellular and organismal metabolism instead of cell proliferation and growth sufficiently necessitate a new unified and specific term for these three endocrine FGFs. Thus, the term “FGF Metabolic Axis,” which distinguishes the unique pathways and functions of endocrine FGFs from other autocrine/paracrine mitogenic FGFs, is coined.
|
Keywords
FGF19
FGF21
FGF23
FGFR
metabolism
endocrine
Klotho
|
Corresponding Author(s):
Xiaokun Li
|
Just Accepted Date: 06 August 2019
Online First Date: 11 September 2019
Issue Date: 14 October 2019
|
|
1 |
A Beenken, M Mohammadi. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009; 8(3): 235–253
https://doi.org/10.1038/nrd2792
pmid: 19247306
|
2 |
Y Luo, S Ye, X Li, W Lu. Emerging structure-function paradigm of endocrine FGFs in metabolic diseases. Trends Pharmacol Sci 2019; 40(2): 142–153
https://doi.org/10.1016/j.tips.2018.12.002
pmid: 30616873
|
3 |
X Li, C Wang, J Xiao, WL McKeehan, F Wang. Fibroblast growth factors, old kids on the new block. Semin Cell Dev Biol 2016; 53: 155–167
https://doi.org/10.1016/j.semcdb.2015.12.014
pmid: 26768548
|
4 |
AE Eriksson, LS Cousens, LH Weaver, BW Matthews. Three-dimensional structure of human basic fibroblast growth factor. Proc Natl Acad Sci USA 1991; 88(8): 3441–3445
https://doi.org/10.1073/pnas.88.8.3441
pmid: 1707542
|
5 |
G Chen, Y Liu, R Goetz, L Fu, S Jayaraman, MC Hu, OW Moe, G Liang, X Li, M Mohammadi. α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature 2018; 553(7689): 461–466
https://doi.org/10.1038/nature25451
pmid: 29342138
|
6 |
C Degirolamo, C Sabbà, A Moschetta. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov 2016; 15(1): 51–69
https://doi.org/10.1038/nrd.2015.9
pmid: 26567701
|
7 |
Y Luo, S Ye, X Chen, F Gong, W Lu, X Li. Rush to the fire: FGF21 extinguishes metabolic stress, metaflammation and tissue damage. Cytokine Growth Factor Rev 2017; 38: 59–65
https://doi.org/10.1016/j.cytogfr.2017.08.001
pmid: 28887067
|
8 |
WL McKeehan, F Wang, M Kan. The heparan sulfate-fibroblast growth factor family: diversity of structure and function. Prog Nucleic Acid Res Mol Biol 1998; 59: 135–176
https://doi.org/10.1016/S0079-6603(08)61031-4
pmid: 9427842
|
9 |
N Itoh, DM Ornitz. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004; 20(11): 563–569
https://doi.org/10.1016/j.tig.2004.08.007
pmid: 15475116
|
10 |
N Itoh, DM Ornitz. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 2011; 149(2): 121–130
https://doi.org/10.1093/jb/mvq121
pmid: 20940169
|
11 |
Y Luo, W Lu, X Li. Unraveling endocrine FGF signaling complex to combat metabolic diseases. Trends Biochem Sci 2018; 43(8): 563–566
https://doi.org/10.1016/j.tibs.2018.05.001
pmid: 29895507
|
12 |
X Zhang, OA Ibrahimi, SK Olsen, H Umemori, M Mohammadi, DM Ornitz. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006; 281(23): 15694–15700
https://doi.org/10.1074/jbc.M601252200
pmid: 16597617
|
13 |
HA Armelin. Pituitary extracts and steroid hormones in the control of 3T3 cell growth. Proc Natl Acad Sci USA 1973; 70(9): 2702–2706
https://doi.org/10.1073/pnas.70.9.2702
pmid: 4354860
|
14 |
D Gospodarowicz. Localisation of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature 1974; 249(453): 123–127
https://doi.org/10.1038/249123a0
pmid: 4364816
|
15 |
WH Burgess, T Maciag. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 1989; 58(1): 575–606
https://doi.org/10.1146/annurev.bi.58.070189.003043
pmid: 2549857
|
16 |
Y Luo, S Ye, M Kan, WL McKeehan. Control of fibroblast growth factor (FGF) 7- and FGF1-induced mitogenesis and downstream signaling by distinct heparin octasaccharide motifs. J Biol Chem 2006; 281(30): 21052–21061
https://doi.org/10.1074/jbc.M601559200
|
17 |
D Gospodarowicz, CR Ill, PJ Hornsby, GN Gill. Control of bovine adrenal cortical cell proliferation by fibroblast growth factor. Lack of effect of epidermal growth factor. Endocrinology 1977; 100(4): 1080–1089
https://doi.org/10.1210/endo-100-4-1080
pmid: 189990
|
18 |
SL Mansour, JM Goddard, MR Capecchi. Mice homozygous for a targeted disruption of the proto-oncogene int-2 have developmental defects in the tail and inner ear. Development 1993; 117(1): 13–28
pmid: 8223243
|
19 |
C Guo, Y Sun, B Zhou, RM Adam, X Li, WT Pu, BE Morrow, A Moon, X Li. A Tbx1-Six1/Eya1-Fgf8 genetic pathway controls mammalian cardiovascular and craniofacial morphogenesis. J Clin Invest 2011; 121(4): 1585–1595
https://doi.org/10.1172/JCI44630
pmid: 21364285
|
20 |
DM Ornitz, PJ Marie. Fibroblast growth factor signaling in skeletal development and disease. Genes Dev 2015; 29(14): 1463–1486
https://doi.org/10.1101/gad.266551.115
pmid: 26220993
|
21 |
M Kan, F Wang, J Xu, JW Crabb, J Hou, WL McKeehan. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 1993; 259(5103): 1918–1921
https://doi.org/10.1126/science.8456318
pmid: 8456318
|
22 |
S Ye, Y Luo, W Lu, RB Jones, RJ Linhardt, I Capila, T Toida, M Kan, H Pelletier, WL McKeehan. Structural basis for interaction of FGF-1, FGF-2, and FGF-7 with different heparan sulfate motifs. Biochemistry 2001; 40(48): 14429–14439
https://doi.org/10.1021/bi011000u
pmid: 11724555
|
23 |
R Goetz, M Mohammadi. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol 2013; 14(3): 166–180
https://doi.org/10.1038/nrm3528
pmid: 23403721
|
24 |
H Kouhara, YR Hadari, T Spivak-Kroizman, J Schilling, D Bar-Sagi, I Lax, J Schlessinger. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 1997; 89(5): 693–702
https://doi.org/10.1016/S0092-8674(00)80252-4
pmid: 9182757
|
25 |
Z Huang, WM Marsiglia, U Basu Roy, N Rahimi, D Ilghari, H Wang, H Chen, W Gai, S Blais, TA Neubert, A Mansukhani, NJ Traaseth, X Li, M Mohammadi. Two FGF receptor kinase molecules act in concert to recruit and transphosphorylate phospholipase Cg. Mol Cell 2016; 61(1): 98–110
https://doi.org/10.1016/j.molcel.2015.11.010
pmid: 26687682
|
26 |
K Dorey, E Amaya. FGF signalling: diverse roles during early vertebrate embryogenesis. Development 2010; 137(22): 3731–3742
https://doi.org/10.1242/dev.037689
pmid: 20978071
|
27 |
W Lu, Y Luo, M Kan, WL McKeehan. Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate. J Biol Chem 1999; 274(18): 12827–12834
https://doi.org/10.1074/jbc.274.18.12827
pmid: 10212269
|
28 |
C Jin, F Wang, X Wu, C Yu, Y Luo, WL McKeehan. Directionally specific paracrine communication mediated by epithelial FGF9 to stromal FGFR3 in two-compartment premalignant prostate tumors. Cancer Res 2004; 64(13): 4555–4562
https://doi.org/10.1158/0008-5472.CAN-03-3752
pmid: 15231666
|
29 |
EP Carter, AE Fearon, RP Grose. Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction. Trends Cell Biol 2015; 25(4): 221–233
https://doi.org/10.1016/j.tcb.2014.11.003
pmid: 25467007
|
30 |
JD Goldberg, J Zheng, H Castro-Malaspina, AA Jakubowski, G Heller, MR van den Brink, MA Perales. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 2013; 48(1): 99–104
https://doi.org/10.1038/bmt.2012.115
pmid: 22750997
|
31 |
H Uchi, A Igarashi, K Urabe, T Koga, J Nakayama, R Kawamori, K Tamaki, H Hirakata, T Ohura, M Furue. Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer. Eur J Dermatol 2009; 19(5): 461–468
pmid: 19638336
|
32 |
S Akita, K Akino, T Imaizumi, A Hirano. Basic fibroblast growth factor accelerates and improves second-degree burn wound healing. Wound Repair Regen 2008; 16(5): 635–641
https://doi.org/10.1111/j.1524-475X.2008.00414.x
pmid: 19128258
|
33 |
X Fu, Z Shen, Y Chen, J Xie, Z Guo, M Zhang, Z Sheng. Randomised placebo-controlled trial of use of topical recombinant bovine basic fibroblast growth factor for second-degree burns. Lancet 1998; 352(9141): 1661–1664
https://doi.org/10.1016/S0140-6736(98)01260-4
pmid: 9853438
|
34 |
L Maddaluno, C Urwyler, S Werner. Fibroblast growth factors: key players in regeneration and tissue repair. Development 2017; 144(22): 4047–4060
https://doi.org/10.1242/dev.152587
pmid: 29138288
|
35 |
YZ Zhao, M Zhang, HL Wong, XQ Tian, L Zheng, XC Yu, FR Tian, KL Mao, ZL Fan, PP Chen, XK Li, CT Lu. Prevent diabetic cardiomyopathy in diabetic rats by combined therapy of aFGF-loaded nanoparticles and ultrasound-targeted microbubble destruction technique. J Control Release 2016; 223: 11–21
https://doi.org/10.1016/j.jconrel.2015.12.030
pmid: 26712588
|
36 |
G Liang, L Song, Z Chen, Y Qian, J Xie, L Zhao, Q Lin, G Zhu, Y Tan, X Li, M Mohammadi, Z Huang. Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism. Kidney Int 2018; 93(1): 95–109
https://doi.org/10.1016/j.kint.2017.05.013
pmid: 28750927
|
37 |
R Li, Y Li, Y Wu, Y Zhao, H Chen, Y Yuan, K Xu, H Zhang, Y Lu, J Wang, X Li, X Jia, J Xiao. Heparin-poloxamer thermosensitive hydrogel loaded with bFGF and NGF enhances peripheral nerve regeneration in diabetic rats. Biomaterials 2018; 168: 24–37
https://doi.org/10.1016/j.biomaterials.2018.03.044
pmid: 29609091
|
38 |
J Wu, J Zhu, C He, Z Xiao, J Ye, Y Li, A Chen, H Zhang, X Li, L Lin, Y Zhao, J Zheng, J Xiao. Comparative study of heparin-poloxamer hydrogel modified bFGF and aFGF for in vivo wound healing efficiency. ACS Appl Mater Interfaces 2016; 8(29): 18710–18721
https://doi.org/10.1021/acsami.6b06047
pmid: 27384134
|
39 |
J Wu, J Ye, J Zhu, Z Xiao, C He, H Shi, Y Wang, C Lin, H Zhang, Y Zhao, X Fu, H Chen, X Li, L Li, J Zheng, J Xiao. Heparin-based coacervate of FGF2 improves dermal regeneration by asserting a synergistic role with cell proliferation and endogenous facilitated VEGF for cutaneous wound healing. Biomacromolecules 2016; 17(6): 2168–2177
https://doi.org/10.1021/acs.biomac.6b00398
pmid: 27196997
|
40 |
Q Wang, Y He, Y Zhao, H Xie, Q Lin, Z He, X Wang, J Li, H Zhang, C Wang, F Gong, X Li, H Xu, Q Ye, J Xiao. A thermosensitive heparin-poloxamer hydrogel bridges aFGF to treat spinal cord injury. ACS Appl Mater Interfaces 2017; 9(8): 6725–6745
https://doi.org/10.1021/acsami.6b13155
pmid: 28181797
|
41 |
M Katoh. Therapeutics targeting FGF signaling network in human diseases. Trends Pharmacol Sci 2016; 37(12): 1081–1096
https://doi.org/10.1016/j.tips.2016.10.003
pmid: 27992319
|
42 |
G Liang, Z Liu, J Wu, Y Cai, X Li. Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol Sci 2012; 33(10): 531–541
https://doi.org/10.1016/j.tips.2012.07.001
pmid: 22884522
|
43 |
P Cuevas, F Carceller, S Ortega, M Zazo, I Nieto, G Giménez-Gallego. Hypotensive activity of fibroblast growth factor. Science 1991; 254(5035): 1208–1210
https://doi.org/10.1126/science.1957172
pmid: 1957172
|
44 |
M Konishi, T Mikami, M Yamasaki, A Miyake, N Itoh. Fibroblast growth factor-16 is a growth factor for embryonic brown adipocytes. J Biol Chem 2000; 275(16): 12119–12122
https://doi.org/10.1074/jbc.275.16.12119
pmid: 10766846
|
45 |
IC Rulifson, P Collins, L Miao, D Nojima, KJ Lee, M Hardy, J Gupte, K Hensley, K Samayoa, C Cam, JB Rottman, M Ollmann, WG Richards, Y Li. In vitro and in vivo analyses reveal profound effects of fibroblast growth factor 16 as a metabolic regulator. J Biol Chem 2017; 292(5): 1951–1969
https://doi.org/10.1074/jbc.M116.751404
pmid: 28011645
|
46 |
JW Jonker, JM Suh, AR Atkins, M Ahmadian, P Li, J Whyte, M He, H Juguilon, YQ Yin, CT Phillips, RT Yu, JM Olefsky, RR Henry, M Downes, RMA Evans. A PPARg-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 2012; 485(7398): 391–394
https://doi.org/10.1038/nature10998
pmid: 22522926
|
47 |
Z Huang, Y Tan, J Gu, Y Liu, L Song, J Niu, L Zhao, L Srinivasan, Q Lin, J Deng, Y Li, DJ Conklin, TA Neubert, L Cai, X Li, M Mohammadi. Uncoupling the mitogenic and metabolic functions of FGF1 by tuning FGF1-FGF receptor dimer stability. Cell Reports 2017; 20(7): 1717–1728
https://doi.org/10.1016/j.celrep.2017.06.063
pmid: 28813681
|
48 |
MK Badman, P Pissios, AR Kennedy, G Koukos, JS Flier, E Maratos-Flier. Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007; 5(6): 426–437
https://doi.org/10.1016/j.cmet.2007.05.002
pmid: 17550778
|
49 |
T Inagaki, M Choi, A Moschetta, L Peng, CL Cummins, JG McDonald, G Luo, SA Jones, B Goodwin, JA Richardson, RD Gerard, JJ Repa, DJ Mangelsdorf, SA Kliewer. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2(4): 217–225
https://doi.org/10.1016/j.cmet.2005.09.001
pmid: 16213224
|
50 |
T Inagaki, P Dutchak, G Zhao, X Ding, L Gautron, V Parameswara, Y Li, R Goetz, M Mohammadi, V Esser, JK Elmquist, RD Gerard, SC Burgess, RE Hammer, DJ Mangelsdorf, SA Kliewer. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab 2007; 5(6): 415–425
https://doi.org/10.1016/j.cmet.2007.05.003
pmid: 17550777
|
51 |
A Kharitonenkov, TL Shiyanova, A Koester, AM Ford, R Micanovic, EJ Galbreath, GE Sandusky, LJ Hammond, JS Moyers, RA Owens, J Gromada, JT Brozinick, ED Hawkins, VJ Wroblewski, DS Li, F Mehrbod, SR Jaskunas, AB Shanafelt. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115(6): 1627–1635
https://doi.org/10.1172/JCI23606
pmid: 15902306
|
52 |
R Goetz, M Ohnishi, X Ding, H Kurosu, L Wang, J Akiyoshi, J Ma, W Gai, Y Sidis, N Pitteloud, OM Kuro, MS Razzaque, M Mohammadi. Klotho co-receptors inhibit signaling by paracrine FGF8 subfamily ligands. Mol Cell Biol 32(10):1944–1954
https://doi.org/10.1128/MCB.06603-11
pmid: 22451487
|
53 |
Y Luo, C Yang, W Lu, R Xie, C Jin, P Huang, F Wang, WL McKeehan. Metabolic regulator βKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation. J Biol Chem 2010; 285(39): 30069–30078
https://doi.org/10.1074/jbc.M110.148288
|
54 |
M Itoh, JC Nacher, K Kuma, S Goto, M Kanehisa. Evolutionary history and functional implications of protein domains and their combinations in eukaryotes. Genome Biol 2007; 8(6): R121
https://doi.org/10.1186/gb-2007-8-6-r121
pmid: 17588271
|
55 |
H Kurosu, M Choi, Y Ogawa, AS Dickson, R Goetz, AV Eliseenkova, M Mohammadi, KP Rosenblatt, SA Kliewer, M Kuro-o. Tissue-specific expression of βKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007; 282(37): 26687–26695
https://doi.org/10.1074/jbc.M704165200
pmid: 17623664
|
56 |
K Fon Tacer, AL Bookout, X Ding, H Kurosu, GB John, L Wang, R Goetz, M Mohammadi, M Kuro-o, DJ Mangelsdorf, SA Kliewer. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 2010; 24(10): 2050–2064
https://doi.org/10.1210/me.2010-0142
pmid: 20667984
|
57 |
H Wang, L Qiang, SR Farmer. Identification of a domain within peroxisome proliferator-activated receptor γ regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol Cell Biol 2008; 28(1): 188–200
https://doi.org/10.1128/MCB.00992-07
pmid: 17954559
|
58 |
K Iizuka, J Takeda, Y Horikawa. Glucose induces FGF21 mRNA expression through ChREBP activation in rat hepatocytes. FEBS Lett 2009; 583(17): 2882–2886
https://doi.org/10.1016/j.febslet.2009.07.053
pmid: 19660458
|
59 |
Y Wang, LA Solt, TP Burris. Regulation of FGF21 expression and secretion by retinoic acid receptor-related orphan receptor α. J Biol Chem 2010; 285(21): 15668–15673
https://doi.org/10.1074/jbc.M110.102160
pmid: 20332535
|
60 |
T Uebanso, Y Taketani, H Yamamoto, K Amo, S Tanaka, H Arai, Y Takei, M Masuda, H Yamanaka-Okumura, E Takeda. Liver X receptor negatively regulates fibroblast growth factor 21 in the fatty liver induced by cholesterol-enriched diet. J Nutr Biochem 2012; 23(7): 785–790
https://doi.org/10.1016/j.jnutbio.2011.03.023
pmid: 21889884
|
61 |
R Masuyama, I Stockmans, S Torrekens, R Van Looveren, C Maes, P Carmeliet, R Bouillon, G Carmeliet. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest 2006; 116(12): 3150–3159
https://doi.org/10.1172/JCI29463
pmid: 17099775
|
62 |
OI Kolek, ER Hines, MD Jones, LK LeSueur, MA Lipko, PR Kiela, JF Collins, MR Haussler, FK Ghishan. 1α,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 2005; 289(6): G1036–G1042
https://doi.org/10.1152/ajpgi.00243.2005
pmid: 16020653
|
63 |
Y Zhang, T Lei, JF Huang, SB Wang, LL Zhou, ZQ Yang, XD Chen. The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes. Mol Cell Endocrinol 2011; 342(1-2): 41–47
https://doi.org/10.1016/j.mce.2011.05.003
pmid: 21664250
|
64 |
TF Liu, JJ Tang, PS Li, Y Shen, JG Li, HH Miao, BL Li, BL Song. Ablation of gp78 in liver improves hyperlipidemia and insulin resistance by inhibiting SREBP to decrease lipid biosynthesis. Cell Metab 2012; 16(2): 213–225
https://doi.org/10.1016/j.cmet.2012.06.014
pmid: 22863805
|
65 |
ES Muise, B Azzolina, DW Kuo, M El-Sherbeini, Y Tan, X Yuan, J Mu, JR Thompson, JP Berger, KK Wong. Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor γ and altered metabolic states. Mol Pharmacol 2008; 74(2): 403–412
https://doi.org/10.1124/mol.108.044826
pmid: 18467542
|
66 |
AL De Sousa-Coelho, PF Marrero, D Haro. Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation. Biochem J 2012; 443(1): 165–171
https://doi.org/10.1042/BJ20111748
pmid: 22233381
|
67 |
C Yang, C Jin, X Li, F Wang, WL McKeehan, Y Luo. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One 2012; 7(3): e33870
https://doi.org/10.1371/journal.pone.0033870
pmid: 22442730
|
68 |
S Lee, J Choi, J Mohanty, LP Sousa, F Tome, E Pardon, J Steyaert, MA Lemmon, I Lax, J Schlessinger. Structures of b-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling. Nature 2018; 553(7689): 501–505
https://doi.org/10.1038/nature25010
pmid: 29342135
|
69 |
Y Luo, WL McKeehan. Stressed liver and muscle call on adipocytes with FGF21. Front Endocrinol (Lausanne) 2013; 4: 194
https://doi.org/10.3389/fendo.2013.00194
pmid: 24385972
|
70 |
SA Harrison, ME Rinella, MF Abdelmalek, JF Trotter, AH Paredes, HL Arnold, M Kugelmas, MR Bashir, MJ Jaros, L Ling, SJ Rossi, AM DePaoli, R Loomba. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2018; 391(10126): 1174–1185
https://doi.org/10.1016/S0140-6736(18)30474-4
pmid: 29519502
|
71 |
GM Hirschfield, O Chazouillères, JP Drenth, D Thorburn, SA Harrison, CS Landis, MJ Mayo, AJ Muir, JF Trotter, DJ Leeming, MA Karsdal, MJ Jaros, L Ling, KH Kim, SJ Rossi, RM Somaratne, AM DePaoli, U Beuers. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial. J Hepatol 2019; 70(3): 483–493
https://doi.org/10.1016/j.jhep.2018.10.035
pmid: 30414864
|
72 |
SA Harrison, SJ Rossi, AH Paredes, JF Trotter, MR Bashir, CD Guy, R Banerjee, MJ Jaros, S Owers, BA Baxter, L Ling, AM DePaoli. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis. Hepatology 2019 Feb 25. [Epub ahead of print] doi:10.1002/hep.30590
pmid: 30805949
|
73 |
A Sanyal, ED Charles, BA Neuschwander-Tetri, R Loomba, SA Harrison, MF Abdelmalek, EJ Lawitz, D Halegoua-DeMarzio, S Kundu, S Noviello, Y Luo, R Christian. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet 2018; 392(10165): 2705–2717
https://doi.org/10.1016/S0140-6736(18)31785-9
pmid: 30554783
|
74 |
S Talukdar, Y Zhou, D Li, M Rossulek, J Dong, V Somayaji, Y Weng, R Clark, A Lanba, BM Owen, MB Brenner, JK Trimmer, KE Gropp, JR Chabot, DM Erion, TP Rolph, B Goodwin, RA Calle. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab 2016; 23(3): 427–440
https://doi.org/10.1016/j.cmet.2016.02.001
pmid: 26959184
|
75 |
TO Carpenter, EA Imel, MD Ruppe, TJ Weber, MA Klausner, MM Wooddell, T Kawakami, T Ito, X Zhang, J Humphrey, KL Insogna, M Peacock. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest 2014; 124(4): 1587–1597
https://doi.org/10.1172/JCI72829
pmid: 24569459
|
76 |
C Yu, F Wang, M Kan, C Jin, RB Jones, M Weinstein, CX Deng, WL McKeehan. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 2000; 275(20): 15482–15489
https://doi.org/10.1074/jbc.275.20.15482
pmid: 10809780
|
77 |
L Fu, LM John, SH Adams, XX Yu, E Tomlinson, M Renz, PM Williams, R Soriano, R Corpuz, B Moffat, R Vandlen, L Simmons, J Foster, JP Stephan, SP Tsai, TA Stewart. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004; 145(6): 2594–2603
https://doi.org/10.1210/en.2003-1671
pmid: 14976145
|
78 |
E Tomlinson, L Fu, L John, B Hultgren, X Huang, M Renz, JP Stephan, SP Tsai, L Powell-Braxton, D French, TA Stewart. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002; 143(5): 1741–1747
https://doi.org/10.1210/endo.143.5.8850
pmid: 11956156
|
79 |
AC Adams, C Yang, T Coskun, CC Cheng, RE Gimeno, Y Luo, A Kharitonenkov. The breadth of FGF21’s metabolic actions are governed by FGFR1 in adipose tissue. Mol Metab 2013; 2(1): 31–37
https://doi.org/10.1016/j.molmet.2012.08.007
pmid: 24024127
|
80 |
JR Walters, AM Tasleem, OS Omer, WG Brydon, T Dew, CW le Roux. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 2009 7(11):1189–1194
https://doi.org/10.1016/j.cgh.2009.04.024
pmid: 19426836
|
81 |
I Oduyebo, M Camilleri, AD Nelson, D Khemani, SL Nord, I Busciglio, D Burton, D Rhoten, M Ryks, P Carlson, L Donato, A Lueke, K Kim, SJ Rossi, AR Zinsmeister. Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial. Am J Gastroenterol 2018; 113(5): 725–734
https://doi.org/10.1038/s41395-018-0042-7
pmid: 29717197
|
82 |
R Pai, D French, N Ma, K Hotzel, E Plise, L Salphati, KD Setchell, J Ware, V Lauriault, L Schutt, D Hartley, D Dambach. Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys. Toxicol Sci 2012; 126(2): 446–456
https://doi.org/10.1093/toxsci/kfs011
pmid: 22268002
|
83 |
GS Gerhard, AM Styer, GC Wood, SL Roesch, AT Petrick, J Gabrielsen, WE Strodel, CD Still, G Argyropoulos. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care 2013; 36(7): 1859–1864
https://doi.org/10.2337/dc12-2255
pmid: 23801799
|
84 |
J Luo, B Ko, M Elliott, M Zhou, DA Lindhout, V Phung, C To, RM Learned, H Tian, AM DePaoli, L Ling. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci Transl Med 2014; 6(247): 247ra100
https://doi.org/10.1126/scitranslmed.3009098
pmid: 25080475
|
85 |
FG Schaap, NA van der Gaag, DJ Gouma, PL Jansen. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009; 49(4): 1228–1235
https://doi.org/10.1002/hep.22771
pmid: 19185005
|
86 |
B Benoit, E Meugnier, M Castelli, S Chanon, A Vieille-Marchiset, C Durand, N Bendridi, S Pesenti, PA Monternier, AC Durieux, D Freyssenet, J Rieusset, E Lefai, H Vidal, J Ruzzin. Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice. Nat Med 2017; 23(8): 990–996
https://doi.org/10.1038/nm.4363
pmid: 28650457
|
87 |
K Nicholes, S Guillet, E Tomlinson, K Hillan, B Wright, GD Frantz, TA Pham, L Dillard-Telm, SP Tsai, JP Stephan, J Stinson, T Stewart, DM French. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 2002; 160(6): 2295–2307
https://doi.org/10.1016/S0002-9440(10)61177-7
pmid: 12057932
|
88 |
M Zhou, RM Learned, SJ Rossi, AM DePaoli, H Tian, L Ling. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology 2016; 63(3): 914–929
https://doi.org/10.1002/hep.28257
pmid: 26418580
|
89 |
MJ Mayo, AJ Wigg, BA Leggett, H Arnold, AJ Thompson, M Weltman, EJ Carey, AJ Muir, L Ling, SJ Rossi, AM DePaoli. NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Commun 2018; 2(9): 1037–1050
https://doi.org/10.1002/hep4.1209
pmid: 30202819
|
90 |
LD BonDurant, MJ Potthoff. Fibroblast growth factor 21: a versatile regulator of metabolic homeostasis. Annu Rev Nutr 2018; 38(1): 173–196
https://doi.org/10.1146/annurev-nutr-071816-064800
pmid: 29727594
|
91 |
C Giannini, AE Feldstein, N Santoro, G Kim, R Kursawe, B Pierpont, S Caprio. Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage. J Clin Endocrinol Metab 2013; 98(7): 2993–3000
https://doi.org/10.1210/jc.2013-1250
pmid: 23626003
|
92 |
Z Lin, Q Gong, C Wu, J Yu, T Lu, X Pan, S Lin, X Li. Dynamic change of serum FGF21 levels in response to glucose challenge in human. J Clin Endocrinol Metab 2012; 97(7): E1224–E1228
https://doi.org/10.1210/jc.2012-1132
pmid: 22539584
|
93 |
Y Yilmaz, F Eren, O Yonal, R Kurt, B Aktas, CA Celikel, O Ozdogan, N Imeryuz, C Kalayci, E Avsar. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 2010; 40(10): 887–892
https://doi.org/10.1111/j.1365-2362.2010.02338.x
pmid: 20624171
|
94 |
SA Kliewer, DJ Mangelsdorf. A dozen years of discovery: insights into the physiology and pharmacology of FGF21. Cell Metab 2019; 29(2): 246–253
https://doi.org/10.1016/j.cmet.2019.01.004
pmid: 30726758
|
95 |
T Laeger, TM Henagan, DC Albarado, LM Redman, GA Bray, RC Noland, H Münzberg, SM Hutson, TW Gettys, MW Schwartz, CD Morrison. FGF21 is an endocrine signal of protein restriction. J Clin Invest 2014; 124(9): 3913–3922
https://doi.org/10.1172/JCI74915
pmid: 25133427
|
96 |
FM Fisher, M Kim, L Doridot, JC Cunniff, TS Parker, DM Levine, MK Hellerstein, LC Hudgins, E Maratos-Flier, MA Herman. A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism. Mol Metab 2017; 6(1): 14–21
https://doi.org/10.1016/j.molmet.2016.11.008
pmid: 28123933
|
97 |
S von Holstein-Rathlou, LD BonDurant, L Peltekian, MC Naber, TC Yin, KE Claflin, AI Urizar, AN Madsen, C Ratner, B Holst, K Karstoft, A Vandenbeuch, CB Anderson, MD Cassell, AP Thompson, TP Solomon, K Rahmouni, SC Kinnamon, AA Pieper, MP Gillum, MJ Potthoff. FGF21 mediates endocrine control of simple sugar intake and sweet taste preference by the liver. Cell Metab 2016; 23(2): 335–343
https://doi.org/10.1016/j.cmet.2015.12.003
pmid: 26724858
|
98 |
S Talukdar, BM Owen, P Song, G Hernandez, Y Zhang, Y Zhou, WT Scott, B Paratala, T Turner, A Smith, B Bernardo, CP Müller, H Tang, DJ Mangelsdorf, B Goodwin, SA Kliewer. FGF21 regulates sweet and alcohol preference. Cell Metab 2016; 23(2): 344–349
https://doi.org/10.1016/j.cmet.2015.12.008
pmid: 26724861
|
99 |
FM Fisher, PC Chui, IA Nasser, Y Popov, JC Cunniff, T Lundasen, A Kharitonenkov, D Schuppan, JS Flier and E Maratos-Flier. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology 2014; 147(5): 1073–1083.e6
https://doi.org/10.1053/j.gastro.2014.07.044
pmid: 25083607
|
100 |
X Huang, C Yu, C Jin, C Yang, R Xie, D Cao, F Wang, WL McKeehan. Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol Carcinog 2006; 45(12): 934–942
https://doi.org/10.1002/mc.20241
pmid: 16929488
|
101 |
N Tanaka, S Takahashi, Y Zhang, KW Krausz, PB Smith, AD Patterson, FJ Gonzalez. Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet. Biochim Biophys Acta 2015; 1852(7): 1242–1252
https://doi.org/10.1016/j.bbadis.2015.02.012
pmid: 25736301
|
102 |
BN Desai, G Singhal, M Watanabe, D Stevanovic, T Lundasen, FM Fisher, ML Mather, HG Vardeh, N Douris, AC Adams, IA Nasser, GA FitzGerald, JS Flier, C Skarke, E Maratos-Flier. Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury. Mol Metab 2017; 6(11): 1395–1406
https://doi.org/10.1016/j.molmet.2017.08.004
pmid: 29107287
|
103 |
D Ye, Y Wang, H Li, W Jia, K Man, CM Lo, Y Wang, KS Lam, A Xu. Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1a-mediated antioxidant capacity in mice. Hepatology 2014; 60(3): 977–989
https://doi.org/10.1002/hep.27060
pmid: 24590984
|
104 |
G Singhal, G Kumar, S Chan, FM Fisher, Y Ma, HG Vardeh, IA Nasser, JS Flier, E Maratos-Flier. Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet. Mol Metab 2018; 13: 56–66
https://doi.org/10.1016/j.molmet.2018.03.002
pmid: 29753678
|
105 |
M Ye, W Lu, X Wang, C Wang, JL Abbruzzese, G Liang, X Li, Y Luo. FGF21-FGFR1 coordinates phospholipid homeostasis, lipid droplet function, and ER stress in obesity. Endocrinology 2016; 157(12): 4754–4769
https://doi.org/10.1210/en.2016-1710
pmid: 27690692
|
106 |
IN Foltz, S Hu, C King, X Wu, C Yang, W Wang, J Weiszmann, J Stevens, JS Chen, N Nuanmanee, J Gupte, R Komorowski, L Sekirov, T Hager, T Arora, H Ge, H Baribault, F Wang, J Sheng, M Karow, M Wang, Y Luo, W McKeehan, Z Wang, MM Véniant, Y Li. Treating diabetes and obesity with an FGF21-mimetic antibody activating the bKlotho/FGFR1c receptor complex. Sci Transl Med 2012; 4(162): 162ra153
https://doi.org/10.1126/scitranslmed.3004690
pmid: 23197570
|
107 |
G Gaich, JY Chien, H Fu, LC Glass, MA Deeg, WL Holland, A Kharitonenkov, T Bumol, HK Schilske, DE Moller. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 2013; 18(3): 333–340
https://doi.org/10.1016/j.cmet.2013.08.005
pmid: 24011069
|
108 |
Z Lin, H Tian, KS Lam, S Lin, RC Hoo, M Konishi, N Itoh, Y Wang, SR Bornstein, A Xu, X Li. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab 2013; 17(5): 779–789
https://doi.org/10.1016/j.cmet.2013.04.005
pmid: 23663741
|
109 |
Z Huang, L Zhong, JTH Lee, J Zhang, D Wu, L Geng, Y Wang, CM Wong, A Xu. The FGF21–CCL11 axis mediates beiging of white adipose tissues by coupling sympathetic nervous system to type 2 immunity. Cell Metab 2017; 26(3): 493–508.e4
https://doi.org/10.1016/j.cmet.2017.08.003
pmid: 28844880
|
110 |
P Lee, JD Linderman, S Smith, RJ Brychta, J Wang, C Idelson, RM Perron, CD Werner, GQ Phan, US Kammula, E Kebebew, K Pacak, KY Chen, FS Celi. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab 2014; 19(2): 302–309
https://doi.org/10.1016/j.cmet.2013.12.017
pmid: 24506871
|
111 |
E Hondares, R Iglesias, A Giralt, FJ Gonzalez, M Giralt, T Mampel, F Villarroya. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem 2011; 286(15): 12983–12990
https://doi.org/10.1074/jbc.M110.215889
pmid: 21317437
|
112 |
M Ameka, KR Markan, DA Morgan, LD BonDurant, SO Idiga, MC Naber, Z Zhu, LV Zingman, JL Grobe, K Rahmouni, MJ Potthoff. Liver derived FGF21 maintains core body temperature during acute cold exposure. Sci Rep 2019; 9(1): 630
https://doi.org/10.1038/s41598-018-37198-y
pmid: 30679672
|
113 |
Y Zhang, Y Xie, ED Berglund, KC Coate, TT He, T Katafuchi, G Xiao, MJ Potthoff, W Wei, Y Wan, RT Yu, RM Evans, SA Kliewer, DJ Mangelsdorf. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. eLife 2012; 1: e00065
https://doi.org/10.7554/eLife.00065
pmid: 23066506
|
114 |
YH Youm, TL Horvath, DJ Mangelsdorf, SA Kliewer, VD Dixit. Prolongevity hormone FGF21 protects against immune senescence by delaying age-related thymic involution. Proc Natl Acad Sci USA 2016; 113(4): 1026–1031
https://doi.org/10.1073/pnas.1514511113
pmid: 26755598
|
115 |
AC Adams, T Coskun, CC Cheng, LS O′Farrell, SL Dubois, A Kharitonenkov. Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones. Mol Metab 2013; 2(3): 205–214
https://doi.org/10.1016/j.molmet.2013.05.005
pmid: 24049735
|
116 |
KC Coate, G Hernandez, CA Thorne, S Sun, TDV Le, K Vale, SA Kliewer, DJ Mangelsdorf. FGF21 is an exocrine pancreas secretagogue. Cell Metab 2017; 25(2): 472–480
https://doi.org/10.1016/j.cmet.2016.12.004
pmid: 28089565
|
117 |
G Singhal, FM Fisher, MJ Chee, TG Tan, A El Ouaamari, AC Adams, R Najarian, RN Kulkarni, C Benoist, JS Flier, E Maratos-Flier. Fibroblast growth factor 21 (FGF21) protects against high fat diet induced inflammation and islet hyperplasia in pancreas. PLoS One 2016; 11(2): e0148252
https://doi.org/10.1371/journal.pone.0148252
pmid: 26872145
|
118 |
CL Johnson, R Mehmood, SW Laing, CV Stepniak, A Kharitonenkov, CL Pin. Silencing of the fibroblast growth factor 21 gene is an underlying cause of acinar cell injury in mice lacking MIST1. Am J Physiol Endocrinol Metab 2014; 306(8): E916–E928
https://doi.org/10.1152/ajpendo.00559.2013
pmid: 24549397
|
119 |
CL Johnson, JY Weston, SA Chadi, EN Fazio, MW Huff, A Kharitonenkov, A Köester, CL Pin. Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology 2009; 137(5): 1795–1804
https://doi.org/10.1053/j.gastro.2009.07.064
pmid: 19664632
|
120 |
M Kuroda, R Muramatsu, N Maedera, Y Koyama, M Hamaguchi, H Fujimura, M Yoshida, M Konishi, N Itoh, H Mochizuki, T Yamashita. Peripherally derived FGF21 promotes remyelination in the central nervous system. J Clin Invest 2017; 127(9): 3496–3509
https://doi.org/10.1172/JCI94337
pmid: 28825598
|
121 |
S Soberg, CH Sandholt, NZ Jespersen, U Toft, AL Madsen, S von Holstein-Rathlou, TJ Grevengoed, KB Christensen, WLP Bredie, MJ Potthoff, TPJ Solomon, C Scheele, A Linneberg, T Jorgensen, O Pedersen, T Hansen, MP Gillum, N Grarup. FGF21 is a sugar-induced hormone associated with sweet intake and preference in humans. Cell Metab 2017; 25(5): 1045–1053.e6
https://doi.org/10.1016/j.cmet.2017.04.009
pmid: 28467924
|
122 |
P Song, C Zechner, G Hernandez, J Canovas, Y Xie, V Sondhi, M Wagner, V Stadlbauer, A Horvath, B Leber, MC Hu, OW Moe, DJ Mangelsdorf, SA Kliewer. The hormone FGF21 stimulates water drinking in response to ketogenic diet and alcohol. Cell Metab 2018; 27(6): 1338–1347.e4
https://doi.org/10.1016/j.cmet.2018.04.001
pmid: 29657029
|
123 |
TM Frayling, RN Beaumont, SE Jones, H Yaghootkar, MA Tuke, KS Ruth, F Casanova, B West, J Locke, S Sharp, Y Ji, W Thompson, J Harrison, AS Etheridge, PJ Gallins, D Jima, F Wright, Y Zhou, F Innocenti, CM Lindgren, N Grarup, A Murray, RM Freathy, MN Weedon, J Tyrrell, AR Wood. A common allele in FGF21 associated with sugar intake is associated with body shape, lower total body-fat percentage, and higher blood pressure. Cell Reports 2018; 23(2): 327–336
https://doi.org/10.1016/j.celrep.2018.03.070
pmid: 29641994
|
124 |
G Schumann, C Liu, P O’Reilly, H Gao, P Song, B Xu, B Ruggeri, N Amin, T Jia, S Preis, M Segura Lepe, S Akira, C Barbieri, S Baumeister, S Cauchi, TK Clarke, S Enroth, K Fischer, J Hällfors, SE Harris, S Hieber, E Hofer, JJ Hottenga, Å Johansson, PK Joshi, N Kaartinen, J Laitinen, R Lemaitre, A Loukola, J Luan, LP Lyytikäinen, M Mangino, A Manichaikul, H Mbarek, Y Milaneschi, A Moayyeri, K Mukamal, C Nelson, J Nettleton, E Partinen, R Rawal, A Robino, L Rose, C Sala, T Satoh, R Schmidt, K Schraut, R Scott, AV Smith, JM Starr, A Teumer, S Trompet, AG Uitterlinden, C Venturini, AC Vergnaud, N Verweij, V Vitart, D Vuckovic, J Wedenoja, L Yengo, B Yu, W Zhang, JH Zhao, DI Boomsma, J Chambers, DI Chasman, T Daniela, E de Geus, I Deary, JG Eriksson, T Esko, V Eulenburg, OH Franco, P Froguel, C Gieger, HJ Grabe, V Gudnason, U Gyllensten, TB Harris, AL Hartikainen, AC Heath, L Hocking, A Hofman, C Huth, MR Jarvelin, JW Jukema, J Kaprio, JS Kooner, Z Kutalik, J Lahti, C Langenberg, T Lehtimäki, Y Liu, PA Madden, N Martin, A Morrison, B Penninx, N Pirastu, B Psaty, O Raitakari, P Ridker, R Rose, JI Rotter, NJ Samani, H Schmidt, TD Spector, D Stott, D Strachan, I Tzoulaki, P van der Harst, CM van Duijn, P Marques-Vidal, P Vollenweider, NJ Wareham, JB Whitfield, J Wilson, B Wolffenbuttel, G Bakalkin, E Evangelou, Y Liu, KM Rice, S Desrivières, SA Kliewer, DJ Mangelsdorf, CP Müller, D Levy, P Elliott. KLB is associated with alcohol drinking, and its gene product b-Klotho is necessary for FGF21 regulation of alcohol preference. Proc Natl Acad Sci USA 2016; 113(50): 14372–14377
https://doi.org/10.1073/pnas.1611243113
pmid: 27911795
|
125 |
LM Restelli, B Oettinghaus, M Halliday, C Agca, M Licci, L Sironi, C Savoia, J Hench, M Tolnay, A Neutzner, A Schmidt, A Eckert, G Mallucci, L Scorrano, S Frank. Neuronal mitochondrial dysfunction activates the integrated stress response to induce fibroblast growth factor 21. Cell Reports 2018; 24(6): 1407–1414
https://doi.org/10.1016/j.celrep.2018.07.023
pmid: 30089252
|
126 |
A Planavila, I Redondo, E Hondares, M Vinciguerra, C Munts, R Iglesias, LA Gabrielli, M Sitges, M Giralt, M van Bilsen, F Villarroya. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun 2013; 4(1): 2019
https://doi.org/10.1038/ncomms3019
pmid: 23771152
|
127 |
T Morville, RE Sahl, SA Trammell, JS Svenningsen, MP Gillum, JW Helge, C Clemmensen. Divergent effects of resistance and endurance exercise on plasma bile acids, FGF19, and FGF21 in humans. JCI Insight 2018; 3(15): 122737
https://doi.org/10.1172/jci.insight.122737
pmid: 30089729
|
128 |
MK Brahma, RC Adam, NM Pollak, D Jaeger, KA Zierler, N Pöcher, R Schreiber, M Romauch, T Moustafa, S Eder, T Ruelicke, K Preiss-Landl, A Lass, R Zechner, G Haemmerle. Fibroblast growth factor 21 is induced upon cardiac stress and alters cardiac lipid homeostasis. J Lipid Res 2014; 55(11): 2229–2241
https://doi.org/10.1194/jlr.M044784
pmid: 25176985
|
129 |
Z Lin, X Pan, F Wu, D Ye, Y Zhang, Y Wang, L Jin, Q Lian, Y Huang, H Ding, C Triggle, K Wang, X Li, A Xu. Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. Circulation 2015; 131(21): 1861–1871
https://doi.org/10.1161/CIRCULATIONAHA.115.015308
pmid: 25794851
|
130 |
SQ Liu, D Roberts, A Kharitonenkov, B Zhang, SM Hanson, YC Li, LQ Zhang, YH Wu. Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Sci Rep 2013; 3(1): 2767
https://doi.org/10.1038/srep02767
pmid: 24067542
|
131 |
H Yang, A Feng, S Lin, L Yu, X Lin, X Yan, X Lu, C Zhang. Fibroblast growth factor-21 prevents diabetic cardiomyopathy via AMPK-mediated antioxidation and lipid-lowering effects in the heart. Cell Death Dis 2018; 9(2): 227
https://doi.org/10.1038/s41419-018-0307-5
pmid: 29445083
|
132 |
C Zhang, Z Huang, J Gu, X Yan, X Lu, S Zhou, S Wang, M Shao, F Zhang, P Cheng, W Feng, Y Tan, X Li. Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signal-regulated kinase 1/2-dependent signalling pathway. Diabetologia 2015; 58(8): 1937–1948
https://doi.org/10.1007/s00125-015-3630-8
pmid: 26040473
|
133 |
X Pan, Y Shao, F Wu, Y Wang, R Xiong, J Zheng, H Tian, B Wang, Y Wang, Y Zhang, Z Han, A Qu, H Xu, A Lu, T Yang, X Li, A Xu, J Du, Z. LinFGF21 prevents angiotensin II–induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1–7) axis in mice. Cell Metab 2018; 27(6): 1323–1337.e5
https://doi.org/10.1016/j.cmet.2018.04.002
pmid: 29706566
|
134 |
KH Kim, YT Jeong, H Oh, SH Kim, JM Cho, YN Kim, SS Kim, DH Kim, KY Hur, HK Kim, T Ko, J Han, HL Kim, J Kim, SH Back, M Komatsu, H Chen, DC Chan, M Konishi, N Itoh, CS Choi, MS Lee. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med 2013; 19(1): 83–92
https://doi.org/10.1038/nm.3014
pmid: 23202295
|
135 |
A Suomalainen, JM Elo, KH Pietiläinen, AH Hakonen, K Sevastianova, M Korpela, P Isohanni, SK Marjavaara, T Tyni, S Kiuru-Enari, H Pihko, N Darin, K Õunap, LA Kluijtmans, A Paetau, J Buzkova, LA Bindoff, J Annunen-Rasila, J Uusimaa, A Rissanen, H Yki-Järvinen, M Hirano, M Tulinius, J Smeitink, H Tyynismaa. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol 2011; 10(9): 806–818
https://doi.org/10.1016/S1474-4422(11)70155-7
pmid: 21820356
|
136 |
L Geng, B Liao, L Jin, Z Huang, CR Triggle, H Ding, J Zhang, Y Huang, Z Lin, A Xu. Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues. Cell Rep 2019; 26(10): 2738–2752.e4
https://doi.org/10.1016/j.celrep.2019.02.014
pmid: 30840894
|
137 |
RO Pereira, SM Tadinada, FM Zasadny, KJ Oliveira, KMP Pires, A Olvera, J Jeffers, R Souvenir, R Mcglauflin, A Seei, T Funari, H Sesaki, MJ Potthoff, CM Adams, EJ Anderson, ED Abel. OPA1 deficiency promotes secretion of FGF21 from muscle that prevents obesity and insulin resistance. EMBO J 2017; 36(14): 2126–2145
https://doi.org/10.15252/embj.201696179
pmid: 28607005
|
138 |
Y Tanimura, W Aoi, Y Takanami, Y Kawai, K Mizushima, Y Naito, T Yoshikawa. Acute exercise increases fibroblast growth factor 21 in metabolic organs and circulation. Physiol Rep 2016; 4(12): e12828
https://doi.org/10.14814/phy2.12828
pmid: 27335433
|
139 |
MS Lee, SE Choi, ES Ha, SY An, TH Kim, SJ Han, HJ Kim, DJ Kim, Y Kang, KW Lee. Fibroblast growth factor-21 protects human skeletal muscle myotubes from palmitate-induced insulin resistance by inhibiting stress kinase and NF-kB. Metabolism 2012; 61(8): 1142–1151
https://doi.org/10.1016/j.metabol.2012.01.012
pmid: 22398021
|
140 |
Y Izumiya, HA Bina, N Ouchi, Y Akasaki, A Kharitonenkov, K Walsh. FGF21 is an Akt-regulated myokine. FEBS Lett 2008; 582(27): 3805–3810
https://doi.org/10.1016/j.febslet.2008.10.021
pmid: 18948104
|
141 |
BM Owen, X Ding, DA Morgan, KC Coate, AL Bookout, K Rahmouni, SA Kliewer, DJ Mangelsdorf. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab 2014; 20(4): 670–677
https://doi.org/10.1016/j.cmet.2014.07.012
pmid: 25130400
|
142 |
N Douris, DM Stevanovic, FM Fisher, TI Cisu, MJ Chee, NL Nguyen, E Zarebidaki, AC Adams, A Kharitonenkov, JS Flier, TJ Bartness, E Maratos-Flier. Central fibroblast growth factor 21 browns white fat via sympathetic action in male mice. Endocrinology 2015; 156(7): 2470–2481
https://doi.org/10.1210/en.2014-2001
pmid: 25924103
|
143 |
Q Liang, L Zhong, J Zhang, Y Wang, SR Bornstein, CR Triggle, H Ding, KS Lam, A Xu. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes 2014; 63(12): 4064–4075
https://doi.org/10.2337/db14-0541
pmid: 25024372
|
144 |
BM Owen, AL Bookout, X Ding, VY Lin, SD Atkin, L Gautron, SA Kliewer, DJ Mangelsdorf. FGF21 contributes to neuroendocrine control of female reproduction. Nat Med 2013; 19(9): 1153–1156
https://doi.org/10.1038/nm.3250
pmid: 23933983
|
145 |
AL Bookout, MH de Groot, BM Owen, S Lee, L Gautron, HL Lawrence, X Ding, JK Elmquist, JS Takahashi, DJ Mangelsdorf, SA Kliewer. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med 2013; 19(9): 1147–1152
https://doi.org/10.1038/nm.3249
pmid: 23933984
|
146 |
N Ishida. Role of PPARa in the control of torpor through FGF21-NPY pathway: from circadian clock to seasonal change in mammals. PPAR Res 2009; 2009: 412949
https://doi.org/10.1155/2009/412949
pmid: 19536348
|
147 |
Q Wang, J Yuan, Z Yu, L Lin, Y Jiang, Z Cao, P Zhuang, MJ Whalen, B Song, XJ Wang, X Li, EH Lo, Y Xu, X Wang. FGF21 attenuates high-fat diet-induced cognitive impairment via metabolic regulation and anti-inflammation of obese mice. Mol Neurobiol 2018; 55(6): 4702–4717
https://doi.org/10.1007/s12035-017-0663-7
pmid: 28712011
|
148 |
Y Yu, F Bai, W Wang, Y Liu, Q Yuan, S Qu, T Zhang, G Tian, S Li, D Li, G Ren. Fibroblast growth factor 21 protects mouse brain against D-galactose induced aging via suppression of oxidative stress response and advanced glycation end products formation. Pharmacol Biochem Behav 2015; 133: 122–131
https://doi.org/10.1016/j.pbb.2015.03.020
pmid: 25871519
|
149 |
DA Sarruf, JP Thaler, GJ Morton, J German, JD Fischer, K Ogimoto, MW Schwartz. Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats. Diabetes 2010; 59(7): 1817–1824
https://doi.org/10.2337/db09-1878
pmid: 20357365
|
150 |
MM Véniant, C Hale, J Helmering, MM Chen, S Stanislaus, J Busby, S Vonderfecht, J Xu, DJ Lloyd. FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. PLoS One 2012; 7(7): e40164
https://doi.org/10.1371/journal.pone.0040164
pmid: 22792234
|
151 |
J Xu, DJ Lloyd, C Hale, S Stanislaus, M Chen, G Sivits, S Vonderfecht, R Hecht, YS Li, RA Lindberg, JL Chen, DY Jung, Z Zhang, HJ Ko, JK Kim, MM Véniant. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58(1): 250–259
https://doi.org/10.2337/db08-0392
pmid: 18840786
|
152 |
WY So, Q Cheng, A Xu, KS Lam, PS Leung. Loss of fibroblast growth factor 21 action induces insulin resistance, pancreatic islet hyperplasia and dysfunction in mice. Cell Death Dis 2015; 6(3): e1707
https://doi.org/10.1038/cddis.2015.80
pmid: 25811804
|
153 |
C Zhang, M Shao, H Yang, L Chen, L Yu, W Cong, H Tian, F Zhang, P Cheng, L Jin, Y Tan, X Li, L Cai, X Lu. Attenuation of hyperlipidemia- and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration of fibroblast growth factor-21 is associated with suppression of renal inflammation. PLoS One 2013; 8(12): e82275
https://doi.org/10.1371/journal.pone.0082275
pmid: 24349242
|
154 |
HW Kim, JE Lee, JJ Cha, YY Hyun, JE Kim, MH Lee, HK Song, DH Nam, JY Han, SY Han, KH Han, YS Kang, DR Cha. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice. Endocrinology 2013; 154(9): 3366–3376
https://doi.org/10.1210/en.2012-2276
pmid: 23825123
|
155 |
TT Tang, YY Li, JJ Li, K Wang, Y Han, WY Dong, ZF Zhu, N Xia, SF Nie, M Zhang, ZP Zeng, BJ Lv, J Jiao, H Liu, ZS Xian, XP Yang, Y Hu, YH Liao, Q Wang, X Tu, Z Mallat, Y Huang, GP Shi, X Cheng. Liver-heart crosstalk controls IL-22 activity in cardiac protection after myocardial infarction. Theranostics 20184552–4562
https://doi.org/10.7150/thno.24723
pmid: 30214638
|
156 |
N Wang, TT Zhao, SM Li, YH Li, YJ Wang, DS Li, WF Wang. Fibroblast growth factor 21 ameliorates pancreatic fibrogenesis via regulating polarization of macrophages. Exp Cell Res 2019; 382(1): 111457
https://doi.org/10.1016/j.yexcr.2019.06.002 [Epub ahead of print]doi:10.1016/j.yexcr.2019.06.002
pmid: 31175853
|
157 |
S Li, X Guo, T Zhang, N Wang, J Li, P Xu, S Zhang, G Ren, D Li. Fibroblast growth factor 21 ameliorates high glucose-induced fibrogenesis in mesangial cells through inhibiting STAT5 signaling pathway. Biomed Pharmacother 2017; 93: 695–704
https://doi.org/10.1016/j.biopha.2017.06.100
pmid: 28692941
|
158 |
S Li, N Wang, X Guo, J Li, T Zhang, G Ren, D Li. Fibroblast growth factor 21 regulates glucose metabolism in part by reducing renal glucose reabsorption. Biomed Pharmacother 2018; 108: 355–366
https://doi.org/10.1016/j.biopha.2018.09.078
pmid: 30227329
|
159 |
XL Lin, XL He, JF Zeng, H Zhang, Y Zhao, JK Tan, Z Wang. FGF21 increases cholesterol efflux by upregulating ABCA1 through the ERK1/2-PPARg-LXRa pathway in THP1 macrophage-derived foam cells. DNA Cell Biol 2014; 33(8): 514–521
https://doi.org/10.1089/dna.2013.2290
pmid: 24735204
|
160 |
Y Yu, J He, S Li, L Song, X Guo, W Yao, D Zou, X Gao, Y Liu, F Bai, G Ren, D Li. Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-kB signaling pathway. Int Immunopharmacol 2016; 38: 144–152
https://doi.org/10.1016/j.intimp.2016.05.026
pmid: 27276443
|
161 |
H Li, G Wu, Q Fang, M Zhang, X Hui, B Sheng, L Wu, Y Bao, P Li, A Xu, W Jia. Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat. Nat Commun 2018; 9(1): 272
https://doi.org/10.1038/s41467-017-02677-9
pmid: 29348470
|
162 |
SM Li, WF Wang, LH Zhou, L Ma, Y An, WJ Xu, TH Li, YH Yu, DS Li, Y Liu. Fibroblast growth factor 21 expressions in white blood cells and sera of patients with gestational diabetes mellitus during gestation and postpartum. Endocrine 2015; 48(2): 519–527
https://doi.org/10.1007/s12020-014-0309-8
pmid: 24895044
|
163 |
JY Li, N Wang, MH Khoso, CB Shen, MZ Guo, XX Pang, DS Li, WF Wang. FGF-21 elevated IL-10 production to correct LPS-induced inflammation. Inflammation 2018; 41(3): 751–759
https://doi.org/10.1007/s10753-018-0729-3
pmid: 29427162
|
164 |
WF Wang, L Ma, MY Liu, TT Zhao, T Zhang, YB Yang, HX Cao, XH Han, DS Li. A novel function for fibroblast growth factor 21: stimulation of NADPH oxidase-dependent ROS generation. Endocrine 2015; 49(2): 385–395
https://doi.org/10.1007/s12020-014-0502-9
pmid: 25542183
|
165 |
SM Li, YH Yu, L Li, WF Wang, DS Li. Treatment of CIA mice with FGF21 down-regulates TH17-IL-17 axis. Inflammation 2016; 39(1): 309–319
https://doi.org/10.1007/s10753-015-0251-9
pmid: 26424095
|
166 |
H Saito, K Kusano, M Kinosaki, H Ito, M Hirata, H Segawa, K Miyamoto, N Fukushima. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1α,25-dihydroxyvitamin D3 production. J Biol Chem 2003; 278(4): 2206–2211
https://doi.org/10.1074/jbc.M207872200
pmid: 12419819
|
167 |
T Shimada, M Kakitani, Y Yamazaki, H Hasegawa, Y Takeuchi, T Fujita, S Fukumoto, K Tomizuka, T Yamashita. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113(4): 561–568
https://doi.org/10.1172/JCI200419081
pmid: 14966565
|
168 |
T Shimada, S Mizutani, T Muto, T Yoneya, R Hino, S Takeda, Y Takeuchi, T Fujita, S Fukumoto, T Yamashita. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98(11): 6500–6505
https://doi.org/10.1073/pnas.101545198
pmid: 11344269
|
169 |
O Andrukhova, A Smorodchenko, M Egerbacher, C Streicher, U Zeitz, R Goetz, V Shalhoub, M Mohammadi, EE Pohl, B Lanske, RG Erben. FGF23 promotes renal calcium reabsorption through the TRPV5 channel. EMBO J 2014; 33(3): 229–246
https://doi.org/10.1002/embj.201284188
pmid: 24434184
|
170 |
O Andrukhova, S Slavic, A Smorodchenko, U Zeitz, V Shalhoub, B Lanske, EE Pohl, RG Erben. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med 2014; 6(6): 744–759
https://doi.org/10.1002/emmm.201303716
pmid: 24797667
|
171 |
IZ Ben-Dov, H Galitzer, V Lavi-Moshayoff, R Goetz, M Kuro-o, M Mohammadi, R Sirkis, T Naveh-Many, J Silver. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117(12): 4003–4008
https://doi.org/10.1172/JCI32409
pmid: 17992255
|
172 |
L Toro, V Barrientos, P León, M Rojas, M Gonzalez, A González-Ibáñez, S Illanes, K Sugikawa, N Abarzúa, C Bascuñán, K Arcos, C Fuentealba, AM Tong, AA Elorza, ME Pinto, R Alzamora, C Romero, L Michea. Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury. Kidney Int 2018; 93(5): 1131–1141
https://doi.org/10.1016/j.kint.2017.11.018
pmid: 29395333
|
173 |
S Rabadi, I Udo, DE Leaf, SS Waikar, M Christov. Acute blood loss stimulates fibroblast growth factor 23 production. Am J Physiol Renal Physiol 2018; 314(1): F132–F139
https://doi.org/10.1152/ajprenal.00081.2017
pmid: 28877877
|
174 |
ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26(3): 345–348
https://doi.org/10.1038/81664
pmid: 11062477
|
175 |
AE Bowe, R Finnegan, SM Jan de Beur, J Cho, MA Levine, R Kumar, SC Schiavi. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 2001; 284(4): 977–981
https://doi.org/10.1006/bbrc.2001.5084
pmid: 11409890
|
176 |
M Riminucci, MT Collins, NS Fedarko, N Cherman, A Corsi, KE White, S Waguespack, A Gupta, T Hannon, MJ Econs, P Bianco, P Gehron Robey. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 2003; 112(5): 683–692
https://doi.org/10.1172/JCI18399
pmid: 12952917
|
177 |
WH Hoffman, HW Jueppner, BR Deyoung, MS O’dorisio, KS Given. Elevated fibroblast growth factor-23 in hypophosphatemic linear nevus sebaceous syndrome. Am J Med Genet A 2005; 134(3): 233–236
https://doi.org/10.1002/ajmg.a.30599
pmid: 15742370
|
178 |
K Kato, C Jeanneau, MA Tarp, A Benet-Pagès, B Lorenz-Depiereux, EP Bennett, U Mandel, TM Strom, H Clausen. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 2006; 281(27): 18370–18377
https://doi.org/10.1074/jbc.M602469200
pmid: 16638743
|
179 |
S Ichikawa, EA Imel, AH Sorenson, R Severe, P Knudson, GJ Harris, JL Shaker, MJ Econs. Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene. J Clin Endocrinol Metab 2006; 91(11): 4472–4475
https://doi.org/10.1210/jc.2006-1247
pmid: 16940445
|
180 |
HJ Garringer, C Fisher, TE Larsson, SI Davis, DL Koller, MJ Cullen, MS Draman, N Conlon, A Jain, NS Fedarko, B Dasgupta, KE White. The role of mutant UDP-N-acetyl-α-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis. J Clin Endocrinol Metab 2006; 91(10): 4037–4042
https://doi.org/10.1210/jc.2006-0305
pmid: 16868048
|
181 |
A Benet-Pagès, P Orlik, TM Strom, B Lorenz-Depiereux. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005; 14(3): 385–390
https://doi.org/10.1093/hmg/ddi034
pmid: 15590700
|
182 |
I Chefetz, R Heller, A Galli-Tsinopoulou, G Richard, B Wollnik, M Indelman, F Koerber, O Topaz, R Bergman, E Sprecher, E Schoenau. A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification. Hum Genet 2005; 118(2): 261–266
https://doi.org/10.1007/s00439-005-0026-8
pmid: 16151858
|
183 |
K Araya, S Fukumoto, R Backenroth, Y Takeuchi, K Nakayama, N Ito, N Yoshii, Y Yamazaki, T Yamashita, J Silver, T Igarashi, T Fujita. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 2005; 90(10): 5523–5527
https://doi.org/10.1210/jc.2005-0301
pmid: 16030159
|
184 |
F Abbasi, S Ghafouri-Fard, M Javaheri, A Dideban, A Ebrahimi, A Ebrahim-Habibi. A new missense mutation in FGF23 gene in a male with hyperostosis-hyperphosphatemia syndrome (HHS). Gene 2014; 542(2): 269–271
https://doi.org/10.1016/j.gene.2014.03.052
pmid: 24680727
|
185 |
C Faul, AP Amaral, B Oskouei, MC Hu, A Sloan, T Isakova, OM Gutiérrez, R Aguillon-Prada, J Lincoln, JM Hare, P Mundel, A Morales, J Scialla, M Fischer, EZ Soliman, J Chen, AS Go, SE Rosas, L Nessel, RR Townsend, HI Feldman, M St John Sutton, A Ojo, C Gadegbeku, GS Di Marco, S Reuter, D Kentrup, K Tiemann, M Brand, JA Hill, OW Moe, M Kuro-O, JW Kusek, MG Keane, M Wolf. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121(11): 4393–4408
https://doi.org/10.1172/JCI46122
pmid: 21985788
|
186 |
OM Gutiérrez, JL Januzzi, T Isakova, K Laliberte, K Smith, G Collerone, A Sarwar, U Hoffmann, E Coglianese, R Christenson, TJ Wang, C deFilippi, M Wolf. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119(19): 2545–2552
https://doi.org/10.1161/CIRCULATIONAHA.108.844506
pmid: 19414634
|
187 |
ER McGrath, JJ Himali, D Levy, SC Conner, MP Pase, CR Abraham, P Courchesne, CL Satizabal, RS Vasan, AS Beiser, S Seshadri. Circulating fibroblast growth factor 23 levels and incident dementia: The Framingham heart study. PLoS One 2019; 14(3): e0213321
https://doi.org/10.1371/journal.pone.0213321
pmid: 30830941
|
188 |
P Liu, L Chen, X Bai, A Karaplis, D Miao, N Gu. Impairment of spatial learning and memory in transgenic mice overexpressing human fibroblast growth factor-23. Brain Res 2011; 1412: 9–17
https://doi.org/10.1016/j.brainres.2011.07.028
pmid: 21824606
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|